Allt fler aktörer vittnar om en mer utmanande IT-marknad till följd av det osäkra makroekonomiska lä...
Fortsatt MRR-tillväxt som tangerar historiska toppnivåer och en välfylld kassa skapar utrymme för ti...
Duell announced the terms of its fully guaranteed rights offering.
Redey comments on Strax Q2 2023 report. An overall messy report with very high COGS and OPEX togethe...
The growth for Free2Move continues, with sales in Q3 and the first nine months representing 21% and ...
Redeye provides an update on ChromoGenics following the company's Q3 2023 results.
Redeye has updated our estimates and fair value range in light of Wyld Networks’ Q3 2023 report, whi...
Finepart publicerade den 23 november 2023 bolagets delårsrapport för det tredje kvartalet år 2023.
EcoRub publicerade den 30 november 2023 bolagets delårsrapport för det tredje kvartalet och visar på...
NOSIUM har publicerat bolagets delårsrapport för det tredje kvartalet 2023.
Redeye concludes that the figures in Wyld’s Q3’23 report aligned with our expectations.
Redeye comments on Ngenic’s Q3 report, where Ngenic reported impressive net sales, which completely ...
Redeye comments on ChromoGenics Q3 2023 report. The cost reduction efforts made throughout the quart...
Akzo Nobel Selektope product on Korean market in 6-12 months Adds Akzo Nobel to list of named custom...
Redeye see a Q3 report from Xbrane that came in slightly above estimates in terms of revenues, but w...
With stable sales in H1’23/24, Qlucore has continued on the revised, more concentrated path announce...
ARR in line (36% y-o-y growth); minor '23e-'25e top-line revisions '23e EBITDA up 8% on abnormally l...
Redeye is encouraged to learn that Alzinova’s lead candidate, ALZ-101, met the primary endpoint of s...
Redeye comments on TECO2030’s Q3 report, which held no major surprises.
Redeye comments on the outcome of the TO 2B announcement published today.
